ValiRx plc (LON:VAL – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 3.30 ($0.04) and last traded at GBX 3.43 ($0.04), with a volume of 3453641 shares traded. The stock had previously closed at GBX 3.63 ($0.05).
ValiRx Price Performance
The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.27 and a current ratio of 13.37. The firm’s 50-day simple moving average is GBX 3.91 and its 200-day simple moving average is GBX 6.80. The company has a market capitalization of £4.57 million, a price-to-earnings ratio of -115.00 and a beta of 0.63.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than ValiRx
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- MarketBeat Week in Review – 4/15 – 4/19
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Comprehensive Analysis of PayPal Stock
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
